New advances in multiple system atrophy

doi:10.3868/j. issn. 2096-0689. 2019. 01. 004

Journal of Translational Neuroscience

2019, Vol. 4

Issue (1) : 38-49 https://doi.org/10.3868/j. issn. 2096-0689. 2019. 01. 004

Review

New advances in multiple system atrophy

Lingyu Zhang, Bei Cao, Huifang Shang^*

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China

Download: PDF(14376 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by a variable combination of autonomic failure, parkinsonism with poor response to levodopa, cerebellar ataxia and pyramidal symptoms. The pathological hallmark of MSA is the oligodendrocytic glial cytoplasmic inclusions (GCIs) consisting of α-synuclein, and so MSA, together with Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), is an α-synucleinopathy. Currently few effective biomarkers have been identified for the diagnosis or prognosis of MSA, and there is no established therapy to delay its progression. In this review, we discuss the epidemiology, neuropathology, genetics, clinical presentation and diagnostic biomarkers of MSA, as well as recent advances in its treatment.

Keywords multiple system atrophy (MSA) neurodegenerative disorder

Issue Date: 25 March 2019

Cite this article:

Lingyu Zhang, Bei Cao, Huifang Shang. New advances in multiple system atrophy[J]. Journal of Translational Neuroscience,2019, 4(1): 38-49.

URL:

http://journal.hep.com.cn/jtn/EN/10.3868/j. issn. 2096-0689. 2019. 01. 004
http://journal.hep.com.cn/jtn/EN/Y2019/V4/I1/38

Service
	E-mail this article
	E-mail Alert
	RSS
Articles by authors

Viewed

Full text

Abstract

Cited

Shared

Discussed